Cite
Evaluation of a New Formulation of Fenofibric Acid, ABT-335, Co-Administered with Statins: Study Design and Rationale of a Phase III Clinical Programme.
MLA
Jones, Peter H., et al. “Evaluation of a New Formulation of Fenofibric Acid, ABT-335, Co-Administered with Statins: Study Design and Rationale of a Phase III Clinical Programme.” Clinical Drug Investigation, vol. 28, no. 10, Oct. 2008, p. 625. EBSCOhost, https://doi.org/10.2165/00044011-200828100-00003.
APA
Jones, P. H., Bays, H. E., Davidson, M. H., Kelly, M. T., Buttler, S. M., Setze, C. M., Sleep, D. J., & Stolzenbach, J. C. (2008). Evaluation of a New Formulation of Fenofibric Acid, ABT-335, Co-Administered with Statins: Study Design and Rationale of a Phase III Clinical Programme. Clinical Drug Investigation, 28(10), 625. https://doi.org/10.2165/00044011-200828100-00003
Chicago
Jones, Peter H., Harold E. Bays, Michael H. Davidson, Maureen T. Kelly, Susan M. Buttler, Carolyn M. Setze, Darryl J. Sleep, and James C. Stolzenbach. 2008. “Evaluation of a New Formulation of Fenofibric Acid, ABT-335, Co-Administered with Statins: Study Design and Rationale of a Phase III Clinical Programme.” Clinical Drug Investigation 28 (10): 625. doi:10.2165/00044011-200828100-00003.